Truist analyst Danielle Brill lowered the firm’s price target on Neurocrine (NBIX) to $140 from $169 and keeps a Buy rating on the shares. The firm has updated its model to reflect the company’s Q4 earnings and the management’s guidance on the outlook for 2026, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine post-earnings selloff overdone, says JPMorgan
- Neurocrine Biosciences Earnings Call Highlights Growth Momentum
- Neurocrine price target lowered to $177 from $180 at RBC Capital
- Neurocrine price target lowered to $185 from $187 at Needham
- Neurocrine price target lowered to $190 from $195 at BofA